Viiv Healthcare UK (no.5) Limited

Bristol-myers Squibb Compnay

Viiv Healthcare UK Limited

Robert A Fridell

Nicholas A Meanwell

Makonen Belema

Alan Xiangdong Wang

John A Bender

Annapurna Pendri

Robert G Gentles

Zhong Yang

Brett R Beno

John F Kadow

Piyasena Hewawasam

Omar D Lopez

Gan Wang

Van N Nguyen

Yong Tu

Manoranjan Panda

Srinivasan Thangathirupathy

Min Gao

Guo Li

Ningning Xu

Rajesh Onkardas Bora

Selvakumar Kumaravel

Samayamunthula Venkata Satya Arun Kumar Gupta

Julie A Lemm

Ying-Kai Wang

Pothukanuri Srinivasu

Mallikarjuna Rao Mettu

Donald R O'Boyle, Ii

Jin-Hua Sun

Shilpa Maheshwarappa Holehatti

Indasi Gopi Kumar

Ponugupati Suresh Kumar

Chunfu Wang

Donald R O'BOYLE Ii

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

Growing community of inventors

Guilford, CT, United States of America

Robert A Fridell